All Themes

CMS under the Trump administration is accelerating mandatory and technology-enabled payment models: CJR’s reported $180M in savings is strengthening the case for broader bundled-payment expansion, while TEAM is already shifting episode economics toward outpatient care and tighter post-acute/home health coordination. At the same time, CMS is expanding the ACCESS Model into additional chronic-condition tracks for 2027—COPD, substance use disorder, tobacco cessation and others—signaling a longer-term push to pair digital infrastructure with longitudinal chronic care management and risk-bearing provider participation ([ACCESS expansion](https://www.healthcaredive.com/news/cms-add-more-chronic-conditions-access-model-2027/830506/)). Regulatory pressure is also rising around coding, drug spend and primary care economics: OIG scrutiny of Medicare Advantage diagnosis submissions reinforces risk-adjustment compliance risk, CMS’s finalized GLOBE drug pricing model adds another cost-control lever, and proposed 2027 Physician Fee Schedule changes would begin rebalancing Medicare payment toward primary care and accountable care participation ([primary care payment changes](https://www.hfma.org/payment-reimbursement-and-managed-care/2027-medicare-primary-care-payment/)). For ACOs, health systems and payers, the strategic signal is clear: CMS is rewarding scalable chronic care, primary care capacity and episode accountability while tightening oversight of documentation, MA coding and high-cost therapeutics.

CMS is accelerating affordability-focused payment reform under the Trump administration, pairing evidence from the Comprehensive Care for Joint Replacement model—reported to have generated $180M in Medicare savings while maintaining quality—with signals that episode-based models could expand nationally, reinforcing downside-risk readiness for hospitals, specialists, and ACO-adjacent networks. At the same time, CMS finalized the GLOBE drug pricing model to apply most-favored-nation-style pricing to Part B drugs, triggering immediate pharma litigation and sharpening the strategic tension between federal savings targets, provider drug-margin exposure, and specialty-care access. Medicare Advantage remains under cost and quality scrutiny, with 2027 Star Ratings supporting bonus payments for high-rated plans even as MedPAC’s $76B overpayment estimate and county-level plan exits raise pressure on payers and risk-bearing providers to prove value through coding integrity, network performance, and benefit sustainability. [CJR savings and expansion implications](https://www.techtarget.com/revcyclemanagement/news/366651340/CJR-Models-180M-savings-pave-way-for-nationwide-expansion) [GLOBE drug pricing model litigation](https://endpoints.news/phrma-sues-trump-administration-over-globe-drug-pricing-demo-program/)

Medicare Advantage is entering a tighter, more selective VBC cycle: 2027 Star Ratings created sharp winners and losers—Humana rebounded while Aetna and Alignment faced pressure—and CMS landscape data show major carriers trimming county footprints and plan offerings, forcing some beneficiaries into plan shopping and signaling that MA growth is being repriced around quality, risk, and margin discipline ([Healthcare Dive](https://www.healthcaredive.com/news/medicare-advantage-stars-2027-winners-losers/832582/), [KFF](https://www.kff.org/medicare/medicare-advantage-plan-availability-varies-widely-by-county-for-2027/)). At the same time, MedPAC’s defense of its $76 billion MA overpayment estimate keeps payment integrity and coding intensity squarely in Congress’s sights, raising strategic risk for MA-dependent provider groups, ACOs, and enablement companies that rely on risk-adjusted revenue. CMMI is also continuing to test tech-enabled population health through the CMS ACCESS model, with Oura and Counsel Health using wearables and AI for chronic care management—evidence that the Trump administration’s CMS, under Dr. Mehmet Oz and CMMI Director Abe Sutton, is pairing MA scrutiny with selective experimentation in scalable, data-driven care models.

CMS is signaling continued commitment to technology-enabled value-based payment under the Trump administration, expanding the 10-year ACCESS Model to additional chronic-condition tracks—COPD, substance use disorder, tobacco cessation, and others—effective in 2027, with agency officials also pointing toward broader cross-payer alignment that could pull Medicaid and commercial stakeholders into similar chronic care accountability frameworks ([Healthcare Dive](https://www.healthcaredive.com/news/cms-add-more-chronic-conditions-access-model-2027/830506/)). At the same time, hospital and provider coalitions are using the CY 2027 Physician Fee Schedule comment cycle to press CMS for ACO-friendly payment policy, lower administrative burden, better interoperability, and incentives that support innovation without weakening quality and outcome accountability ([Premier](https://premierinc.com/newsroom/policy/premier-provides-cms-feedback-on-physician-payment-and-value-based-care-proposals-for-cy-2027)). Together, these moves suggest VBC strategy is shifting from isolated Medicare demonstrations toward chronic disease platforms, digital enablement, and multi-payer scalability—while providers remain focused on whether payment updates and reporting requirements make participation financially viable.

CMS is moving care coordination deeper into chronic disease management and post-acute referral networks: the Trump administration’s expansion of the 10-year ACCESS Model adds heart failure, COPD, substance use disorders, and tobacco use tracks effective April 2027, signaling a broader push to pair value-based payment with digital tools, wearables, AI-enabled coaching, and scalable longitudinal monitoring for Medicare beneficiaries ([HFMA](https://www.hfma.org/payment-reimbursement-and-managed-care/cms-access-model-expansion/)). At the same time, early TEAM implementation is reshaping hospital discharge strategy by tightening preferred referral relationships with home health and SNF partners, pressuring post-acute providers to prove reliability on readmissions, episode cost, data exchange, and capacity as hospitals manage mandatory episode accountability ([Home Health Care News](https://homehealthcarenews.com/2026/09/9-months-in-team-pushes-outpatient-services-tighter-home-health-coordination/)). For ACOs, health systems, and payers, the strategic through-line is clear: referral management, home-based care coordination, and tech-enabled chronic care are becoming core infrastructure for VBC performance rather than optional care management add-ons.

CMS is pushing health IT from “connectivity” toward operational accountability in VBC: the ACCESS model is adding wearables and AI-enabled chronic care vendors such as Oura and Counsel Health to test scalable remote monitoring and longitudinal engagement, while Medicaid quality efforts with 37 states are shifting measurement toward outcomes rather than checklist compliance. At the same time, implementation risk is rising as WISeR exposes delays and technical failures in AI-enabled prior authorization, and stakeholders including the AMA are pressing CMS to hold firm on electronic prior authorization deadlines—making interoperability, workflow integration, and governance core strategic risks for ACOs, Medicare Advantage plans, Medicaid agencies, and risk-bearing providers rather than back-office IT issues. See: [ACCESS model technology expansion](https://www.fiercehealthcare.com/health-tech/oura-counsel-health-cms-access-model) and [WISeR AI prior authorization challenges](https://www.fiercehealthcare.com/regulatory/delays-tech-failures-abound-cms-wiser-ai-prior-auth-pilot-documents-show).

CMS is moving quality measurement deeper into episode- and condition-based payment design: CJR’s reported $180M in Medicare savings while maintaining quality is strengthening the case for broader mandatory or quasi-mandatory episode models, while TEAM is already pushing hospitals toward tighter outpatient, post-acute, and home health coordination. At the same time, the Trump administration is expanding the technology-enabled ACCESS Model into additional chronic conditions for 2027, signaling a longer-term shift toward scalable population health infrastructure, digital monitoring, and cross-payer alignment—but with continued tension around administrative burden, interoperability, and whether quality accountability keeps pace with model expansion ([CJR savings and expansion case](https://www.techtarget.com/revcyclemanagement/news/366651340/CJR-Models-180M-savings-pave-way-for-nationwide-expansion); [ACCESS chronic condition expansion](https://www.healthcaredive.com/news/cms-add-more-chronic-conditions-access-model-2027/830506/)).

CMS is pushing Medicaid value-based care further toward outcomes accountability, with 37 states joining a Trump administration initiative to streamline quality measurement around whether beneficiaries get healthier rather than whether plans and providers satisfy process-heavy reporting requirements—an important signal for Medicaid managed care plans, ACOs, and provider groups preparing for tighter alignment between quality, data infrastructure, and payment. At the same time, Medicaid ACO activity is becoming more targeted around equity-sensitive populations, especially maternal health, as Massachusetts Medicaid ACO initiatives and broader research on midwifery workforce authority point to care-model levers that can improve access and outcomes for high-risk pregnant members. The strategic tension for VBC stakeholders is that outcome-based Medicaid redesign is advancing alongside eligibility and coverage pressures—including community engagement/work requirements and legal immigrant coverage losses—which could destabilize attribution, continuity, and population health ROI unless plans and ACOs invest in enrollment retention, interoperability, and community-based care management ([CMS/state Medicaid quality initiative](https://www.fiercehealthcare.com/regulatory/37-states-partner-cms-initiative-rethink-medicaid-quality-measures); [Massachusetts Medicaid ACO maternal health initiatives](https://hooperlundy.com/massachusetts-medicaid-acos-initiatives-improve-maternal-health/)).

Payment integrity is moving to the center of Medicare Advantage and VBC strategy as HHS OIG audits, DOJ False Claims Act activity, and CMS oversight converge on diagnosis-code validity, risk adjustment, and overpayment recoupment—most recently with OIG findings against UnitedHealthcare and Humana MA contracts and DOJ’s [$22.5M Independence Blue Cross settlement](https://www.justice.gov/opa/pr/independence-blue-cross-pay-225m-resolve-false-claims-act-allegations). At the same time, CMMI under Director Abe Sutton is positioning the [WISeR prior authorization model](https://www.hfma.org/cmmi-head-wiser-should-serve-as-model/) as a broader template for using AI-enabled utilization controls to reduce “wasteful and inappropriate” services in Medicare, despite provider concerns over delays, administrative burden, and technology failures. For ACOs, MA plans, and risk-bearing providers, the signal is clear: growth in risk-based payment will be paired with tighter scrutiny of coding, documentation, utilization management, and model governance, raising the strategic premium on compliant risk adjustment, defensible clinical workflows, and audit-ready data infrastructure.

CMS is positioning the ACCESS Model as a broader population health and chronic disease management platform, expanding it to additional chronic conditions while signaling interest in cross-payer alignment across Medicare and Medicaid—an important structural shift for ACOs, Medicaid managed care plans, and provider groups building longitudinal care management infrastructure ([Fierce Healthcare](https://www.fiercehealthcare.com/regulatory/cms-extends-access-model-more-chronic-conditions-cms-officials-eye-expansion-medicaid)). The model’s inclusion of technology-enabled participants such as Oura and Counsel Health underscores a Trump administration push under CMS leadership to test whether wearables, AI-enabled triage, and remote monitoring can scale chronic care interventions, but it also raises familiar VBC tensions around attribution, data integration, equity, and whether digital engagement can translate into measurable total-cost-of-care savings ([Healthcare IT News](https://www.healthcareitnews.com/news/cms-expands-access-model-cover-more-chronic-conditions)). At the same time, MSSP growth and reported Medicare savings are reinforcing that population health is moving from pilot activity to operating model discipline, with strategic advantage shifting to organizations that can coordinate outreach, close care gaps, manage high-risk cohorts, and navigate Medicaid eligibility or work-requirement churn without losing covered lives.

CMS is positioning primary care as a central VBC lever, with the 2027 Physician Fee Schedule proposing a two-year strategy to address Medicare’s longstanding undervaluation of primary care while the ACCESS Model expands to additional chronic conditions and brings in technology partners such as Oura and Counsel Health to test AI- and wearable-enabled chronic care at scale. The strategic direction is toward higher prospective investment, chronic-condition management, and cross-payer alignment, but the tension for ACOs and health systems is whether new payments and digital infrastructure will reduce administrative burden and improve outcomes—or simply add another layer of model complexity and measurement requirements. See HFMA on the [2027 Medicare primary care payment changes](https://www.hfma.org/payment-reimbursement-and-managed-care/2027-medicare-primary-care-payment/) and Fierce Healthcare on the [ACCESS Model expansion](https://www.fiercehealthcare.com/health-tech/oura-counsel-health-cms-access-model).

CMS and HHS oversight of Medicare Advantage risk adjustment is tightening, with new OIG audits alleging unsupported diagnosis codes at UnitedHealthcare and Humana MA contracts and estimating large overpayments tied to coding intensity—reinforcing that VBC revenue strategies dependent on retrospective chart reviews, in-home assessments, and aggressive HCC capture face rising audit and repayment risk. DOJ’s $22.5M False Claims Act settlement with Independence Blue Cross over MA diagnosis coding further signals that risk adjustment compliance is becoming a core enforcement front, not just a technical CMS reconciliation issue, as payers and delegated provider groups absorb more downside exposure in MA and value-based contracts. For ACOs, health systems, and payer partners, the strategic shift is toward prospective, encounter-based documentation integrity and defensible population risk stratification, as MedPAC’s high MA overpayment estimates and Trump administration CMS scrutiny increase pressure to separate legitimate complexity coding from revenue-maximizing upcoding ([OIG MA compliance audits](https://oig.hhs.gov/reports/all/2026/medicare-advantage-compliance-audit-of-specific-diagnosis-codes-that-humanachoice-contract-h5216-submitted-to-cms/); [DOJ Independence Blue Cross settlement](https://www.justice.gov/opa/pr/independence-blue-cross-pay-225m-resolve-false-claims-act-allegations)).

Medicare Advantage contracting is entering a tighter, more uneven 2027 cycle: CMS landscape data show fewer MA-PD options in many counties, major insurer county exits, and an average of 28 MA-PD choices per beneficiary, while disruption in markets like Minnesota is forcing large-scale beneficiary plan switching—raising network, attribution, and continuity risks for VBC providers and ACO-aligned delivery systems ([KFF analysis](https://www.kff.org/medicare/medicare-advantage-plan-availability-varies-widely-by-county-for-2027/)). At the same time, CMS under Administrator Dr. Mehmet Oz is signaling continued MA oversight—particularly around plan behavior, post-acute utilization, and durable medical equipment supplier controls—despite projecting lower 2027 premiums, creating a contracting environment where payers are narrowing footprints and providers will need stronger evidence on access, utilization management performance, risk adjustment integrity, and total-cost-of-care outcomes ([Healthcare Dive](https://www.healthcaredive.com/news/oz-medicare-advantage-garden-weeds-bma-cms/831062/)).

Medicare Advantage strategy is being reshaped by a sharper enforcement-and-revenue squeeze: HHS OIG audits of UnitedHealthcare and Humana contracts found diagnosis-code unsupported payments, while DOJ’s $22.5M Independence Blue Cross FCA settlement reinforces that risk adjustment documentation, chart review, and coding governance are now board-level compliance issues for MA plans and delegated risk entities. At the same time, 2027 Star Ratings dynamics are creating uneven strategic positioning—more enrollment is concentrated in 4+ star MA-PD contracts eligible for quality bonus payments, but changing cut points and lower reward-factor thresholds could pressure 2028 rebates and supplemental-benefit funding, forcing plans and provider partners to prioritize measurable quality performance over pure membership growth ([HFMA on 2027 Stars](https://www.hfma.org/payment-reimbursement-and-managed-care/2027-medicare-advantage-star-ratings/); [OIG MA coding audits](https://oig.hhs.gov/reports/all/2026/medicare-advantage-compliance-audit-of-specific-diagnosis-codes-that-humanachoice-contract-h5216-submitted-to-cms/)). For VBC stakeholders, the near-term implication is a tighter operating model for MA risk: stronger prospective clinical documentation, defensible population-health interventions tied to encounter evidence, and more rigorous Stars execution will be essential as CMS and enforcement agencies scrutinize whether coding intensity reflects real care complexity rather than revenue optimization.

CMS is pushing specialty and drug-spend accountability deeper into provider operations, finalizing the mandatory GLOBE Part B drug payment model while narrowing its scope and projected savings—an approach that still shifts infusion economics, pharmacy strategy, and service-line margin management for hospitals, oncology practices, and other Part B drug-heavy providers. At the same time, CMS released participant lists for the 2027 Ambulatory Specialty Model and CJR-X joint replacement model, signaling continued reliance on mandatory or quasi-mandatory episode and specialty models alongside ACO-style population accountability. The strategic tension for VBC stakeholders is operational readiness versus policy/legal uncertainty: providers must prepare for model participation, drug acquisition/payment redesign, and specialty cost controls even as pharma litigation challenges the Trump administration’s GLOBE model [finalization](https://www.aha.org/news/headline/2026-10-01-cms-finalizes-globe-drug-pricing-model) and specialty societies track narrowed financial exposure [in the final rule](https://news.google.com/rss/articles/CBMivwFBVV95cUxNdXZ3cU0wSHhMVlRtTkM0N2ozWHh4ZzE4VFpOS04tRzg4RDFlR3U1cUdVZWc2M1EzWE11aXhkaFFndnhJc1FVNzN3dEZwdVFzN1EzQVpITnItLUM)

ACO strategy is being shaped by a near-term payment-policy squeeze and a longer-term primary care revaluation: CMS’s CY 2027 Physician Fee Schedule proposals would begin addressing primary care undervaluation while potentially reducing average physician reimbursement, intensifying the need for MSSP and ACO REACH participants to use care management, coding accuracy, and specialty-alignment strategies to protect margins. Stakeholders including Premier and AHA are pushing CMS to strengthen accountable care participation, reduce administrative burden, and improve interoperability, while industry groups such as HCTTF and new direct-contracting coalitions are positioning around more flexible risk arrangements beyond traditional MSSP constructs. The strategic signal for health systems and ACOs is that VBC growth is continuing—MSSP now covers a record 12.6 million beneficiaries and generated $2.4 billion in net Medicare savings—but success will depend less on joining a model and more on building an operating model that converts primary care investment into measurable total-cost and quality performance ([HFMA on VBC operating model](https://www.hfma.org/finance-and-business-strategy/from-fragmented-outreach-to-coordinated-action-building-a-value-based-care-operating-model/); [Premier CMS feedback](https://premierinc.com/newsroom/policy/premier-provides-cms-feedback-on-physician-payment-and-value-based-care-proposals-for-cy-2027)).

CMS is moving bundled payments from demonstration evidence toward broader mandatory adoption: CJR’s reported $180M in Medicare savings is being used to support expansion through CJR-X, while TEAM is already accelerating outpatient migration and tighter post-acute/home health coordination for surgical episodes. The strategic tension for hospitals, ACOs, and conveners is that Medicare’s site-of-care and episode-payment policies are converging—especially as inpatient joint replacement volumes become smaller and higher-acuity—forcing redesign of orthopedic pathways, discharge networks, and risk analytics to protect margins under mandatory bundles. Medicaid maternity VBP activity adds a parallel signal that episode-based accountability is spreading beyond Medicare surgical care into population-focused state payment reform. [CJR savings and expansion](https://www.techtarget.com/revcyclemanagement/news/366651340/CJR-Models-180M-savings-pave-way-for-nationwide-expansion); [TEAM outpatient/home health shift](https://homehealthcarenews.com/2026/09/9-months-in-team-pushes-outpatient-services-tighter-home-health-coordination/)

CMS is moving specialty value-based care from pilot rhetoric toward mandatory, operationally specific models: the agency finalized the 2027 Ambulatory Specialty Model participant list, while physician groups such as the Texas Medical Association are pushing for delay—signaling growing provider concern over mandatory attribution, benchmarking, and administrative readiness ([ACC](https://www.acc.org/Latest-in-Cardiology/Articles/2026/09/15/18/42/CMS-Releases)). At the same time, specialty societies are positioning around the 2027 Medicare Physician Fee Schedule and QPP/MVP architecture, with cardiology and sleep medicine seeking to shape quality measures, telehealth, remote monitoring, and specialty-specific reporting pathways before they become embedded in payment. Oncology and kidney care developments point to a second front: CMS narrowed the financial exposure of the GLOBE Part B drug pricing model, while external scrutiny of virtual CKD management and community oncology bundled-payment design is intensifying the debate over whether specialty VBC can generate measurable cost and outcome gains without destabilizing access or practice economics ([ASCO](https://news.google.com/rss/articles/CBMivwFBVV95cUxNdXZ3cU0wSHhMVlRtTkM0N2ozWHh4ZzE4VFpOS04tRzg4RDFlR3U1cUdVZWc2M1EzWE11aXhkaFFndnhJc1FVNzN)